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Sir,
Dr Otto claimed potential improvement in the sensitivity of
immunochemical faecal occult blood testing (IFOBT) by combining
faecal albumin detection with IFOBT (Otto and Dobrossy, 2004). As
was indicated in their letter, the American Cancer Society special
advisory group stated that IFOBT is the only exception to the
conclusion that there is insufficient evidence to recommend any
emerging technologies as a routine screening test for colorectal
cancer (Levin et al, 2003). Although this statement needs to be
further explained and thus will be discussed later, the point is that
IFOBT has been certified as an efficacious tool in terms of evidence.
Accordingly, the test used by Dr Otto might be of importance if it
could demonstrate even better sensitivity and specificity than those
seen with IFOBT, such as the immunochemical haemagglutination
test (Saito et al, 1984; Saito and Yoshida, 1996).
Since parallel testing generally enhances sensitivity of single
testing, it is possible that the addition of faecal albumin detection
to IFOBT might improve sensitivity as compared to the detection
of faecal haemoglobin alone. The data described in Dr Otto’s letter,
however, failed to demonstrate the sensitivity of the test in the
population, nor did it compare its sensitivity with that of other
IFOBT. Although performance characteristics of many available
IFOBTs appear generally to be high, difference in sensitivity and
specificity among these immunochemical FOBTs has been
reported (Saito and Yoshida, 1996). The method employed by Dr
Otto and a colleague is a combination test involving immuno-
chemical detection of faecal haemoglobin and albumin, and the
sensitivity of their faecal haemoglobin test is unclear. Therefore,
the test needs to be compared with IFOBT in the same population
for their conclusion to be justified.
Degradation of haemoglobin during transit through the gastro-
intestinal tract is a well-known phenomenon. Haemoglobin from
lesions proximal to the colon is generally believed to lose its
antigenicity, a fact that confers an advantage to IFOBT, because a
positive test is specific for bleeding from lesions in the colon
(Young et al, 2002). During transit within the colon, loss of
antigenicity also occurs depending on the duration of exposure of
haemoglobin to microbial flora. Thus, in theory, colorectal cancer
in proximal colonic sites such as the caecum might be more likely
to be missed by FOBT. However, it was reported that the sensitivity
of IFOBT does not differ between proximal and distal cancers (St
John et al, 1993). This could be because the effect of bacterial
degradation of immunoreactive haemoglobin during transit
through the colon might be offset by the high sensitivity of the
IFOBT and the fact that proximal lesions bleed more heavily
(Macrae and St John, 1982; St John et al, 1992). As a result, there
has been no firm evidence that sensitivity of FOBT is reduced due
to degradation of haemoglobin during transit in the colon.
False-negative testing after degradation of haemoglobin is
important in terms of storage of specimens; that is, haemoglobin
loses its antigenicity with duration of storage depending on the
temperature (Saito et al, 1992). Thus, seeking a marker other than
haemoglobin in faeces is a reasonable approach. From this point of
view, we measured plasma proteins (immunoglobulin, albumin,
transferrin, a1-acid glycoprotein and complements) in faeces, but
could not find any that remained significantly more stable than
haemoglobin.
Although the IFOBT is treated as an emerging technology in the
field of population screening (Levin et al, 2003), this is not the case
for the immunochemical haemagglutination test, which we devel-
oped (Saito et al, 1984; Saito, 1996). This has already been used as a
population screening test and a reduction in risk of dying from
colorectal cancer after screening with this test has been consistently
suggested by several studies, although these were observational
(Saito et al, 1995, 2000; Saito, 1996; Zappa et al, 1997). In our most
recent study, reduction in risk of developing advanced colorectal
cancer has additionally been suggested (Nakajima et al, 2003).
Furthermore, it was demonstrated that sensitivity was higher for
this test than for the Haemoccult test (St John et al, 1993; Allison
et al, 1996; Saito and Yoshida, 1996). Taking into consideration the
fact that this test does not require dietary restriction, it
undoubtedly has the advantage over the Haemoccult, for which
effectiveness has been established. Incorporating IFOBT, including
the immunochemical haemagglutination test, the Japanese national
screening programme has been run using two-day IFOBT since
1992 with more than 5 million screenees annually.
It is now clearly recognised in many countries, in which the
burden of colorectal cancer is serious, that screening should be
conducted aimed at reducing the mortality of this disease.
Although sensitivity of the IFOBT is not total, it should be the
preferred option in terms of evidence, among the modalities
available as population screening tools at the present time.
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